VivoSeq
Other

Scleroderma, Diffuse

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Scleroderma, Diffuse is an early-stage landscape with 2 programs across 2 companies. The most active players are Novartis, Roche.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Rapcabtagene Autoleucel

Novartis

Rituximab

Roche

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

2programs
Monoclonal antibody150%
Cell therapy150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis
Recruiting·Novartis logoNovartis·Phase 2·NCT06655896·96 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)